Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM

H. Hanaire-Broutin, B. Sallerin-Caute, M. F. Poncet, M. Tauber, R. Bastide, J. J. Chalé, Ronald (Ron) Rosenfeld, J. P. Tauber

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Low plasma insulin-like growth factor (IGF)-I despite high circulating growth hormone (GH) in insulin-dependent diabetes mellitus (IDDM) indicate a hepatic GH resistance. This state may be reflected by the reduction of the circulating GH binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, and the reduction of insulin-like growth factor binding protein (IGFBP)-3, major IGF-I binding protein, upregulated by GH. We carried out two studies. In the first, plasma GHBP activity was compared in patients with IDDM on continuous subcutaneous insulin infusion (CSII) or on conventional therapy and in healthy subjects. In the second study, the 18 patients on GSII at baseline were then treated by continuous intraperitoneal insulin infusion with an implantable pump (CPII) and prospectively studied for GH-IGF-I axis. Although HbA(1c) was lower in patients on CSII than in those on conventional therapy, GHBP was similarly reduced in both when compared to control subjects (10.2 ± 0.8 and 11.6 ± 0.9% vs 21.0 ± 1.3, p <0.01). CPII for 12 months resulted in: a slight and transient improvement in HbA(1c) (Time (T)0: 7.6 ± 0.2%, T3: 7.1 ± 0.2%, T12: 7.5 ± 0.2%, p <0.02), improvement in GHBP (T0: 10.2 ± 0.8%, T12: 15.5 ± 1.5, p <0.0001), near-normalization of IGF-I (T0: 89.4 ± 8.8 ng/ml, T12: 146.9 ± 15.6, p <0.002) and normalization of IGFBP-3 (T0: 1974 ± 121 ng/ml, T12: 3534 ± 305, p <0.0001). The hepatic GH resistance profile in IDDM does not seem to be related to glycaemic control, but partly to insufficient portal insulinization. Intraperitoneal insulin delivery, allowing primary portal venous absorption, may influence GH sensitivity, and improve hepatic IGF-I and IGFBP-3 generation.

Original languageEnglish (US)
Pages (from-to)1498-1504
Number of pages7
JournalDiabetologia
Volume39
Issue number12
DOIs
StatePublished - 1996

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Type 1 Diabetes Mellitus
Insulin-Like Growth Factor I
Growth Hormone
Insulin
Subcutaneous Infusions
Liver
Parenteral Infusions
Somatotropin Receptors
Insulin-Like Growth Factor Binding Proteins
somatotropin-binding protein
Healthy Volunteers
Therapeutics

Keywords

  • growth hormone binding protein
  • IGF binding proteins
  • implantable pumps
  • insulin-depedent diabetes mellitus
  • insulin-like growth factor I

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Hanaire-Broutin, H., Sallerin-Caute, B., Poncet, M. F., Tauber, M., Bastide, R., Chalé, J. J., ... Tauber, J. P. (1996). Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia, 39(12), 1498-1504. https://doi.org/10.1007/s001250050604

Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. / Hanaire-Broutin, H.; Sallerin-Caute, B.; Poncet, M. F.; Tauber, M.; Bastide, R.; Chalé, J. J.; Rosenfeld, Ronald (Ron); Tauber, J. P.

In: Diabetologia, Vol. 39, No. 12, 1996, p. 1498-1504.

Research output: Contribution to journalArticle

Hanaire-Broutin, H, Sallerin-Caute, B, Poncet, MF, Tauber, M, Bastide, R, Chalé, JJ, Rosenfeld, RR & Tauber, JP 1996, 'Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM', Diabetologia, vol. 39, no. 12, pp. 1498-1504. https://doi.org/10.1007/s001250050604
Hanaire-Broutin, H. ; Sallerin-Caute, B. ; Poncet, M. F. ; Tauber, M. ; Bastide, R. ; Chalé, J. J. ; Rosenfeld, Ronald (Ron) ; Tauber, J. P. / Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. In: Diabetologia. 1996 ; Vol. 39, No. 12. pp. 1498-1504.
@article{4cc3bd0f56354e9fba193c834b55aaab,
title = "Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM",
abstract = "Low plasma insulin-like growth factor (IGF)-I despite high circulating growth hormone (GH) in insulin-dependent diabetes mellitus (IDDM) indicate a hepatic GH resistance. This state may be reflected by the reduction of the circulating GH binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, and the reduction of insulin-like growth factor binding protein (IGFBP)-3, major IGF-I binding protein, upregulated by GH. We carried out two studies. In the first, plasma GHBP activity was compared in patients with IDDM on continuous subcutaneous insulin infusion (CSII) or on conventional therapy and in healthy subjects. In the second study, the 18 patients on GSII at baseline were then treated by continuous intraperitoneal insulin infusion with an implantable pump (CPII) and prospectively studied for GH-IGF-I axis. Although HbA(1c) was lower in patients on CSII than in those on conventional therapy, GHBP was similarly reduced in both when compared to control subjects (10.2 ± 0.8 and 11.6 ± 0.9{\%} vs 21.0 ± 1.3, p <0.01). CPII for 12 months resulted in: a slight and transient improvement in HbA(1c) (Time (T)0: 7.6 ± 0.2{\%}, T3: 7.1 ± 0.2{\%}, T12: 7.5 ± 0.2{\%}, p <0.02), improvement in GHBP (T0: 10.2 ± 0.8{\%}, T12: 15.5 ± 1.5, p <0.0001), near-normalization of IGF-I (T0: 89.4 ± 8.8 ng/ml, T12: 146.9 ± 15.6, p <0.002) and normalization of IGFBP-3 (T0: 1974 ± 121 ng/ml, T12: 3534 ± 305, p <0.0001). The hepatic GH resistance profile in IDDM does not seem to be related to glycaemic control, but partly to insufficient portal insulinization. Intraperitoneal insulin delivery, allowing primary portal venous absorption, may influence GH sensitivity, and improve hepatic IGF-I and IGFBP-3 generation.",
keywords = "growth hormone binding protein, IGF binding proteins, implantable pumps, insulin-depedent diabetes mellitus, insulin-like growth factor I",
author = "H. Hanaire-Broutin and B. Sallerin-Caute and Poncet, {M. F.} and M. Tauber and R. Bastide and Chal{\'e}, {J. J.} and Rosenfeld, {Ronald (Ron)} and Tauber, {J. P.}",
year = "1996",
doi = "10.1007/s001250050604",
language = "English (US)",
volume = "39",
pages = "1498--1504",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM

AU - Hanaire-Broutin, H.

AU - Sallerin-Caute, B.

AU - Poncet, M. F.

AU - Tauber, M.

AU - Bastide, R.

AU - Chalé, J. J.

AU - Rosenfeld, Ronald (Ron)

AU - Tauber, J. P.

PY - 1996

Y1 - 1996

N2 - Low plasma insulin-like growth factor (IGF)-I despite high circulating growth hormone (GH) in insulin-dependent diabetes mellitus (IDDM) indicate a hepatic GH resistance. This state may be reflected by the reduction of the circulating GH binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, and the reduction of insulin-like growth factor binding protein (IGFBP)-3, major IGF-I binding protein, upregulated by GH. We carried out two studies. In the first, plasma GHBP activity was compared in patients with IDDM on continuous subcutaneous insulin infusion (CSII) or on conventional therapy and in healthy subjects. In the second study, the 18 patients on GSII at baseline were then treated by continuous intraperitoneal insulin infusion with an implantable pump (CPII) and prospectively studied for GH-IGF-I axis. Although HbA(1c) was lower in patients on CSII than in those on conventional therapy, GHBP was similarly reduced in both when compared to control subjects (10.2 ± 0.8 and 11.6 ± 0.9% vs 21.0 ± 1.3, p <0.01). CPII for 12 months resulted in: a slight and transient improvement in HbA(1c) (Time (T)0: 7.6 ± 0.2%, T3: 7.1 ± 0.2%, T12: 7.5 ± 0.2%, p <0.02), improvement in GHBP (T0: 10.2 ± 0.8%, T12: 15.5 ± 1.5, p <0.0001), near-normalization of IGF-I (T0: 89.4 ± 8.8 ng/ml, T12: 146.9 ± 15.6, p <0.002) and normalization of IGFBP-3 (T0: 1974 ± 121 ng/ml, T12: 3534 ± 305, p <0.0001). The hepatic GH resistance profile in IDDM does not seem to be related to glycaemic control, but partly to insufficient portal insulinization. Intraperitoneal insulin delivery, allowing primary portal venous absorption, may influence GH sensitivity, and improve hepatic IGF-I and IGFBP-3 generation.

AB - Low plasma insulin-like growth factor (IGF)-I despite high circulating growth hormone (GH) in insulin-dependent diabetes mellitus (IDDM) indicate a hepatic GH resistance. This state may be reflected by the reduction of the circulating GH binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, and the reduction of insulin-like growth factor binding protein (IGFBP)-3, major IGF-I binding protein, upregulated by GH. We carried out two studies. In the first, plasma GHBP activity was compared in patients with IDDM on continuous subcutaneous insulin infusion (CSII) or on conventional therapy and in healthy subjects. In the second study, the 18 patients on GSII at baseline were then treated by continuous intraperitoneal insulin infusion with an implantable pump (CPII) and prospectively studied for GH-IGF-I axis. Although HbA(1c) was lower in patients on CSII than in those on conventional therapy, GHBP was similarly reduced in both when compared to control subjects (10.2 ± 0.8 and 11.6 ± 0.9% vs 21.0 ± 1.3, p <0.01). CPII for 12 months resulted in: a slight and transient improvement in HbA(1c) (Time (T)0: 7.6 ± 0.2%, T3: 7.1 ± 0.2%, T12: 7.5 ± 0.2%, p <0.02), improvement in GHBP (T0: 10.2 ± 0.8%, T12: 15.5 ± 1.5, p <0.0001), near-normalization of IGF-I (T0: 89.4 ± 8.8 ng/ml, T12: 146.9 ± 15.6, p <0.002) and normalization of IGFBP-3 (T0: 1974 ± 121 ng/ml, T12: 3534 ± 305, p <0.0001). The hepatic GH resistance profile in IDDM does not seem to be related to glycaemic control, but partly to insufficient portal insulinization. Intraperitoneal insulin delivery, allowing primary portal venous absorption, may influence GH sensitivity, and improve hepatic IGF-I and IGFBP-3 generation.

KW - growth hormone binding protein

KW - IGF binding proteins

KW - implantable pumps

KW - insulin-depedent diabetes mellitus

KW - insulin-like growth factor I

UR - http://www.scopus.com/inward/record.url?scp=0029857842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029857842&partnerID=8YFLogxK

U2 - 10.1007/s001250050604

DO - 10.1007/s001250050604

M3 - Article

C2 - 8960832

AN - SCOPUS:0029857842

VL - 39

SP - 1498

EP - 1504

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -